Understanding Corticotropin Releasing Factor Receptor (CRFR) Activation Using Structural Models

被引:0
|
作者
Cordomi, Arnau [1 ]
Liapakis, George [2 ]
Matsoukas, Minos-Timotheos [1 ,3 ]
机构
[1] Univ Autonoma Barcelona, Fac Med, Unitat Bioestat, Lab Med Computac, Bellaterra 08193, Barcelona, Spain
[2] Univ Crete, Fac Med, Dept Pharmacol, Iraklion 71003, Crete, Greece
[3] Univ Patras, Lab Mol Pharmacol, Dept Pharm, Patras 26500, Greece
关键词
Activation; corticotropin releasing factor; family B; GPCR structure; molecular modeling; CRF receptors; PROTEIN-COUPLED RECEPTOR; 2ND TRANSMEMBRANE HELIX; 1ST EXTRACELLULAR DOMAIN; CLASS-B GPCRS; LIGAND-BINDING; ANTAGONIST-BINDING; CRYSTAL-STRUCTURE; NMR STRUCTURE; PEPTIDE; FAMILY;
D O I
10.2174/187446/7210666170110122939
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The corticotropin-releasing factor type 1 and 2 receptors (CRF1R and CRF2R) belong to the secretin-like family, also known as class B1, of G protein-coupled receptors (GPCRs). Several endogenous hormones mediate their responses through the CRF receptors, such as CRF and the urocortins. The structures for the N-terminus extracellular domain of both CRF1R and CRF2R in complex with peptidic ligands were released a few years ago and permitted the study of hormone binding to the orthosteric binding site. Until the crystal structure of the transmembrane domain of human CRF1R in its inactive state bound to an allosteric antagonist became available. Together with the crystal structures of the transmembrane domain of the glucagon receptor (GCGR), they have enabled the structural alignment between the rhodopsin and secretin-like families, which permits the direct comparison of the functional domains in both classes. In this report, we review the current structural landscape, in addition to the knowledge regarding activation of both CRF receptors and the generalization to secretin-like GPCRs in general. Thus, significant effort was put in trying to identify possible analogous microswitches in the class B1, with the hypothesis that both families could maintain a similar arrangement of their functional domain.
引用
收藏
页码:325 / 333
页数:9
相关论文
共 50 条
  • [41] CARDIOVASCULAR ACTIVATION BY SEROTONERGIC STIMULATION - ROLE OF CORTICOTROPIN-RELEASING FACTOR
    DEDEOGLU, A
    FISHER, LA
    AMERICAN JOURNAL OF PHYSIOLOGY, 1994, 267 (03): : R859 - R864
  • [42] Activation of corticotropin-releasing factor receptor-2 causes bronchorelaxation and inhibits pulmonary inflammation in mice
    Moffatt, James D.
    Lever, Rebecca
    Page, Clive P.
    FASEB JOURNAL, 2006, 20 (11): : 1877 - +
  • [43] Androgen Regulation of Corticotropin Releasing Factor Receptor 1 in the Mouse Brain
    Rybka, Krystyna A.
    Sturm, Kassandra L.
    De Guzman, Rose M.
    Bah, Saoudatou
    Jacobskind, Jason S.
    Rosinger, Zachary J.
    Taroc, Ed Zandro M.
    Forni, Paolo E.
    Zuloaga, Damian G.
    NEUROSCIENCE, 2022, 491 : 185 - 199
  • [44] Corticotropin releasing factor receptor antagonists:: potential future therapy in gastroenterology?
    Taché, Y
    GUT, 2004, 53 (07) : 919 - 921
  • [45] Synthesis of substituted pyrimidines as corticotropin releasing factor (CRF) receptor ligands
    Kuppast, Bhimanna
    Spyridaki, Katerina
    Liapakis, George
    Fahmy, Hesham
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2014, 78 : 1 - 9
  • [46] Corticotropin releasing factor receptor expression in painful human dental pulp
    Uhrich, Elizabeth
    Gautam, Medha
    Hatton, John
    Rowland, Kevin
    ARCHIVES OF ORAL BIOLOGY, 2015, 60 (07) : 1048 - 1053
  • [47] Corticotropin-releasing factor receptor 2 is a tonic suppressor of vascularization
    Bale, TL
    Giordano, FJ
    Hickey, RP
    Huang, Y
    Nath, AK
    Peterson, KL
    Vale, WW
    Lee, KF
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (11) : 7734 - 7739
  • [48] Brain pharmacokinetics of a nonpeptidic corticotropin-releasing factor receptor antagonist
    Keller, C
    Bruelisauer, A
    Lemaire, M
    Enz, A
    DRUG METABOLISM AND DISPOSITION, 2002, 30 (02) : 173 - 176
  • [49] N-phenylphenylglycines as novel corticotropin releasing factor receptor antagonists
    Molteni, V
    Penzotti, J
    Wilson, DM
    Termin, AP
    Mao, L
    Crane, CM
    Hassman, F
    Wang, T
    Wong, H
    Miller, KJ
    Grossman, S
    Grootenhuis, PDJ
    JOURNAL OF MEDICINAL CHEMISTRY, 2004, 47 (10) : 2426 - 2429
  • [50] Corticotropin-releasing factor 1 receptor antagonists: a patent review
    Williams, John P.
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2013, 23 (08) : 1057 - 1068